1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
617F2D4F4D70CBD4265257D2D0039E5FF
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-digital-marketing-excellence-brand-relationships-analytics-data-governance?opendocument
18
19opendocument
203.84.139.101
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Sales and Marketing Marketing Management Managing Marketing Organizations Organizational Structure Marketing Organization

Digital Marketing Excellence: Brand Relationships, Analytics and Data Governance

ID: 5318


Features:

18 Info Graphics

19 Data Graphics

200+ Metrics


Pages/Slides: 47


Published: 2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Digital Marketing Excellence: Brand Relationships, Analytics, and Data Governance"

STUDY OVERVIEW

Faced with a rapidly evolving healthcare environment, biopharmaceutical companies are relying on innovative digital marketing strategies to effectively reach out to customers throughout the product lifecycle. This research examines how pharmaceutical companies optimize their digital service delivery to support internal customers and nurture strong digital-brand partnerships. The study also explores the use of analytics for better digital marketing insights and current approaches to data governance within the pharma sector.


The study will help digital marketing leaders better understand the utilization of mobile tools to improve customer engagement and sales force effectiveness, the deployment of advanced analytics for better targeting and performance, and the current state of data governance in pharma.

This study delivers segment perspectives on large, mid-cap and small companies as well as global vs. U.S.-only companies.


KEY TOPICS

  • Study Overview
  • Key Findings & Trends
  • Building Strong Brand Relationships
  • Deploying Advanced Analytics
  • Steps Toward Greater Data Governance Effectiveness

SAMPLE KEY METRICS
  • Effective brand relationship building activities
  • Lessons learned for supporting new product launches
  • Mobile / “second screen” activities significantly impacting market and customers
  • Impact of various activities in supporting field teams using iPads or other tablets
  • Analytics team structure
  • Innovative digital analytics approaches
  • High impact analytics
  • Data governance standards
  • Tactics for promoting adherence to data governance standards

SAMPLE KEY FINDINGS
  • Digital Groups Are Becoming Savvier Brand Partners: Compared with 2013 benchmark data, DM groups are taking more steps to effectively support Brand team customers. Today, DMers train traditional marketers more often (80% of companies vs. 65% in 2013), are more active on joint committees (77% vs. 73%) and are much more likely to engage in co-hiring decisions for new marketing hires (63% vs. 35%).
  • Data Governance Responsibility Rarely Owned by Digital or Analytics Team: Responsibility for data governance appears fractured across a host of different groups. Data governance is most often driven by Function Leadership (at 26% of companies) or IT / MIS (26%). An analytics group, whether Digital team-affiliated or not, leads data governance at just 23% of companies.

METHODOLOGY

Best Practices, LLC engaged 48 Digital Marketing leaders at 42 companies through a benchmarking survey instrument. Representatives from 8 companies participated in deep-dive interviews.

Industries Profiled:
Pharmaceutical; Marketing; Diagnostic; Health Care; Consumer Products; Biotech; Biopharmaceutical; Clinical Research; Laboratories; Medical Device; Science


Companies Profiled:
Teva Pharmaceutical Industries Ltd; Triplefin; Chiesi; biokit; Abbott; Precision Therapeutics; Abbvie; Meridian Bioscience; Merck; Vivus; Bayer Healthcare; MD Outlook; Sanofi; Pfizer; Takeda Pharmaceuticals; Roche; Boehringer Ingelheim; GlaxoSmithKline ; Amgen; Novo Nordisk; Covidien; LEO Pharma; Biogen Idec; Olympus Corporation; Eisai; Mylan; UCB Pharma; Ferring Pharmaceuticals; Lundbeck; Catalent Pharma Solutions; Astellas; CSL Behring; Ranbaxy; Galderma; Boston Scientific; Edward Lifesciences; Purdue Pharma; Nektar Therapeutics; Merial; Genomic Health; Cochlear; Haemonetics Corporation

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.